JPRN-jRCT1031220116
Active, not recruiting
未知
Real-world Effectiveness and Safety of Trifluridine/Tipiracil plus bevacizumab in Metastatic Colorectal Cancer: A retrospective observational study using an administrative database
Taiho Pharmaceutical Co., Ltd. Medical Affairs Division0 sites11,962 target enrollmentJune 4, 2022
ConditionsColorectal cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Colorectal cancer
- Sponsor
- Taiho Pharmaceutical Co., Ltd. Medical Affairs Division
- Enrollment
- 11962
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with CRC aged over 20 years who were diagnosed between May 2014 and January 2021 by using the International Classification of Diseases, 10th revision (ICD\-10\) codes in the database.
- •\-Patients who received FTD/TPI and/or regorafenib.
Exclusion Criteria
- •1\) FTD/TPI\- or regorafenib\-treated patients with diseases other than CRC;
- •2\) patients who received other chemotherapy except bevacizumab simultaneously with FTD/TPI
- •3\) patients who received other chemotherapy simultaneously with regorafenib.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Pooled safety and efficacy analysis of trifluridine/tipiracil plus bevacizumab in five clinical trials using individual data from patients with metastatic colorectal cancermetastatic colorectal cancerJPRN-UMIN000041621The 22nd Century Cutting-Edge Medical Informaion Technology Organization239
Active, not recruiting
Phase 1
Efficacy and safety of Trifluridine/Tipiracil in combination with Irinotecan as a secondline therapy in patients with bile duct cancerPatients with advanced, non resectable or metastatic cholangio- and gallbladder carcinoma after failure to respond to a previous gemcitabine treatment.Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-002936-26-DEHeinrich-Heine-University Düsseldorf28
Completed
Phase 4
A clinical trial to study the effect of Triflusal in Aspirin resitant patientsCTRI/2011/04/001679Glenmark Pharmaceuticals Lts40
Not yet recruiting
Not Applicable
A retrospective observational study of trifluridine tipiracil plus minus bevacizumab in pretreated mCRC patients with MSI-H MMR-D metastatic colorectal cancerJPRN-UMIN000051378The 22nd Century Cutting-Edge Medical Informaion Technology Organization15
Active, not recruiting
Phase 1
Safety of Trifluridine/tipiracil in patients with dihydropyrimidine dehydrogenase deficiency diagnosed with metastatic colorectal or gastroesophageal cancerCTIS2023-508724-35-00nicancer73